Abgenix Press Releases
 
2006 Abgenix Press Releases
Date Title  (click to view the full text PDF)
February 21, 2006 Abgenix Announces 2005 Fourth Quarter and Full Year Financial Results
February 14, 2006 Abgenix to Host Fourth Quarter and Full Year 2005 Conference Call
January 05, 2006 Abgenix to Present at JPMorgan 24th Annual Healthcare Conference

 
2005 Abgenix Press Releases
Date Title  (click to view the full text PDF)
December 14, 2005 Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
December 14, 2005 Amgen to Acquire Abgenix for $22.50 Per Share
November 09, 2005 Abgenix Appoints Jeffrey H. Knapp as Senior Vice President of Sales and Marketing
November 03, 2005 Panitumumab Significantly Improves Progression-Free Survival in Phase 3 Randomized Metastatic Colorectal Cancer Study
November 03, 2005 Media Notification/Webcast Notification - Amgen and Abgenix to Conduct Conference Call and Webcast Regarding Panitumumab Pivotal Study Results - November 3, 2005, 8:00 am PT
October 25, 2005 Abgenix Announces Third Quarter 2005 Financial Results
October 18, 2005 Abgenix to Host Third Quarter 2005 Conference Call
September 01, 2005 Abgenix to Webcast Three Upcoming Conference Presentations
August 01, 2005 Abgenix and Amgen Announce FDA Grants Panitumumab Fast Track Designation for Metastatic Colorectal Cancer
July 26, 2005 Abgenix Announces Second Quarter 2005 Financial Results
July 19, 2005 Abgenix to Host Conference Call on Second Quarter 2005 Financial Results
June 28, 2005 Abgenix to Consolidate Research Facilities in Preparation for Expanded Development and Commercial Operations
June 08, 2005 Abgenix to Present at Goldman Sachs Twenty-Sixth Annual Global Healthcare Conference
May 20, 2005 Abgenix to Present at Needham & Company's Fourth Annual Biotechnology Conference
May 17, 2005 Further Phase 2 Data Confirm Panitumumab Single-Agent Antitumor Activity in Patients With Metastatic Colorectal Cancer
May 11, 2005 Abgenix Appoints Marc Better, Ph.D., as Vice President of Process Sciences
April 26, 2005 Phase 3 Clinical Trial Initiated to Evaluate the Use of Panitumumab Therapy For First-Line Treatment of Metastatic Colorectal Cancer
April 26, 2005 Abgenix Announces First Quarter 2005 Financial Results
April 18, 2005 Abgenix to Host Conference Call on First Quarter 2005 Financial Results
April 15, 2005 Abgenix Announces Data Presentations for Panitumumab at AACR and ASCO Annual Meetings
March 23, 2005 Abgenix to Present at the Smith Barney Citigroup 2005 Healthcare Conference
March 18, 2005 Panitumumab Pivotal Trial Completes Patient Enrollment
March 17, 2005 Abgenix Files Resale Registration Statement
March 14, 2005 Abgenix and Genentech Extend Antibody Technology Licensing Agreement
March 04, 2005 Abgenix Appoints Donald R. Joseph as Senior Vice President, General Counsel and Secretary
February 23, 2005 Abgenix to Webcast Participation in SunTrust Robinson Humphrey 'Off the Cuff' Therapeutics Conference
February 22, 2005 Abgenix Announces 2004 Fourth Quarter and Full Year Financial Results
February 18, 2005 Abgenix to Present at BIO CEO & Investor Conference 2005
February 15, 2005 Abgenix to Host Conference Call on Fourth Quarter and Full Year 2004 Financial Results
February 03, 2005 Abgenix to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
January 20, 2005 Abgenix Appoints Kristen M. Anderson as Senior Vice President of Human Resources
January 13, 2005 Abgenix to Receive Milestone Payment from Amgen for Advancement of Product Candidate into Clinical Trials; Eleventh XenoMouse Antibody Advances to the Clinical Phase
January 12, 2005 Abgenix to Receive Milestone Payment from Chiron for Advancement of Oncology Antibody; Tenth XenoMouse Antibody Advances to the Clinical Phase
January 10, 2005 Abgenix Receives Milestone Payment from Human Genome Sciences for Advancement of CCR5 Antibody Product Candidate; Ninth XenoMouse Antibody Advances to the Clinical Phase
January 07, 2005 Abgenix to Present at JP Morgan 23rd Annual Healthcare Conference

 
2004 Abgenix Press Releases
Date Title  (click to view the full text PDF)
December 15, 2004 Abgenix Announces Pricing of Private Offering of Convertible Senior Notes
December 14, 2004 Abgenix Announces Proposed Private Offering of Convertible Senior Notes
November 23, 2004 Abgenix to Present at Lazard's Life Sciences Conference
November 18, 2004 Abgenix to Receive Milestone Payment from CuraGen for Advancement of CR002 Antibody Product Candidate into Clinic
November 15, 2004 Abgenix to Present at Credit Suisse First Boston Annual Healthcare Conference
November 01, 2004 Interim Phase 2 Data Suggest Activity of Panitumumab with Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
October 26, 2004 Abgenix Announces Third Quarter 2004 Financial Results
October 19, 2004 Abgenix to Host Conference Call on Third Quarter 2004 Financial Results
October 04, 2004 ADVISORY/Abgenix Provides Background Information on Fully Human Antibodies
October 03, 2004 Abgenix Announces Positive Clinical Trial Results for ABX10241 Antibody Product Candidate
September 29, 2004 Abgenix Announces Data Presentations for Product Candidates at Upcoming Medical Meetings
September 20, 2004 Abgenix to Present at UBS Global Life Sciences Conference
September 08, 2004 Abgenix Appoints H. Ward Wolff as Chief Financial Officer
August 13, 2004 Abgenix to Receive Milestone Payment from Amgen for Advancement of Antibody Candidate from Technology Licensing Agreement
July 27, 2004 Abgenix Announces Second Quarter 2004 Financial Results
July 21, 2004 Abgenix to Host Conference Call on Second Quarter 2004 Financial Results
July 20, 2004 Abgenix Appoints William R. Ringo as New CEO and President
June 14, 2004 Abgenix to Present at Needham & Company's Third Annual Biotechnology Conference
June 06, 2004 Interim Phase 2 Data Show Panitumumab Has Single-Agent Antitumor Activity in Metastatic Colorectal Cancer
June 03, 2004 Abgenix to Present at Goldman Sachs Twenty-Fifth Annual Global Healthcare Conference
April 27, 2004 Abgenix Announces First Quarter 2004 Financial Results
April 19, 2004 Abgenix to Host Conference Call on First Quarter 2004 Financial Results
March 15, 2004 ADVISORY/Abgenix Scales Up!; Abgenix to Hold Private Job Fair to Recruit for Large Number of Jobs in Manufacturing and Quality
February 24, 2004 Abgenix Announces 2003 Fourth Quarter and Full Year Financial Results
February 18, 2004 Abgenix to Present at 6th Annual BIO CEO & Investor Conference
February 17, 2004 Abgenix to Host Conference Call on Fourth Quarter and Full Year 2003 Financial Results
February 03, 2004 Abgenix Begins Phase 1 Study of ABX-PTH in Patients with Secondary Hyperparathyroidism
January 30, 2004 Abgenix to Receive Milestone Payment from Pfizer for Third IND from Ongoing Collaboration
January 28, 2004 Abgenix to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
January 20, 2004 Abgenix Announces ABX-EGF Enters Pivotal Trial in Advanced Colorectal Cancer Patients
January 08, 2004 Abgenix to Present at JP Morgan 22nd Annual Healthcare Conference

 
2003 Abgenix Press Releases
Date Title  (click to view the full text PDF)
December 22, 2003 Abgenix Announces Departure of Chief Financial Officer
October 29, 2003 Abgenix and AstraZeneca Successfully Close Equity Transaction for New Oncology Alliance
October 21, 2003 Abgenix Announces Third Quarter 2003 Financial Results
October 20, 2003 Abgenix Receives State of California Certification for New Biologics Manufacturing Facility
October 16, 2003 AstraZeneca and Abgenix Announce Strategic Alliance to Discover and Develop Antibody Therapeutics for Cancer
October 14, 2003 Abgenix to Host Conference Call on Third Quarter 2003 Financial Results
October 14, 2003 Abgenix and Amgen Clarify Responsibilities for ABX-EGF
September 19, 2003 Abgenix to Present at Annual UBS Life Sciences Conference
September 04, 2003 Abgenix to Present at Bear Stearns 16th Annual Healthcare Conference
July 22, 2003 Abgenix Announces Second Quarter 2003 Financial Results
July 16, 2003 Abgenix to Receive IND Milestone Payment from Pfizer
July 15, 2003 Abgenix to Host Conference Call on Second Quarter 2003 Financial Results
June 09, 2003 CuraGen Announces Results of CR002 Study Honored with a Congress Award at the World Congress of Nephrology Meeting
June 05, 2003 Abgenix to Present at Goldman Sachs Twenty-Fourth Annual Global Healthcare Conference
May 31, 2003 Interim Phase 2 Data Demonstrate Single-Agent Antitumor Activity with ABX-EGF in Advanced Colorectal Cancer
May 12, 2003 Human Genome Sciences Acquires License from Abgenix For Human Monoclonal Antibody to Key HIV/AIDS Receptor
May 07, 2003 Microscience and Abgenix Form Alliance to Develop Monoclonal Antibodies in Infectious Disease
April 23, 2003 Abgenix Announces First Quarter 2003 Financial Results
April 22, 2003 Abgenix Appoints Two New Board Members; Ken Lee and Thomas Wiggans Add Industry and Operations Perspective
April 16, 2003 Abgenix to Host Conference Call on First Quarter 2003 Financial Results
March 31, 2003 Abgenix and Sosei to Codevelop Antibodies against Allergic Inflammation Target
February 20, 2003 Abgenix Announces Fourth Quarter 2002 And Full Year Financial Results
February 18, 2003 Study Of ABX-CBL In Steroid Resistant Graft Versus Host Disease Does Not Meet Primary Endpoint
February 03, 2003 Abgenix And Chugai Collaborate To Develop And Manufacture Antibody Therapeutics
January 09, 2003 CuraGen and Abgenix Announce Progress in Antibody Alliance and Sign New Agreement for Antibody Production
January 06, 2003 Abgenix to Present At JP Morgan H&Q 21st Annual Healthcare Conference

 
2002 Abgenix Press Releases
Date Title  (click to view the full text PDF)
October 22, 2002 Abgenix Announces Third Quarter 2002 Results
August 20, 2002 Abgenix Reaffirms Optimism Regarding ABX-EGF
July 23, 2002 Abgenix Reports Second Quarter 2002 Financial Results
June 11, 2002 Abgenix And U3 Pharma Form Collaboration To Develop Therapeutic Antibodies For Cancer
May 21, 2002 Preliminary Phase 2 Data Suggest ABX-EGF Has Single-Agent Anti-Tumor Activity in Advanced Kidney Cancer
May 20, 2002 ABX-EGF Phase 1 Data Indicate Biological Activity as Monotherapy in Multiple Cancers
May 14, 2002 Phase 2b ABX-IL8 Study In Psoriasis Does Not Meet Primary Efficacy Endpoint
May 14, 2002 Abgenix And Corvas Form Collaboration To Develop Therapeutic Antibodies Against Cancer
May 14, 2002 Phase 2b ABX-IL8 Study In Psoriasis Does Not Meet Primary Efficacy Endpoint
May 07, 2002 ILEX Oncology, Inc. Enters Licensing Agreement With Abgenix, Inc. To Develop Novel Antibody Therapy For Cancer
April 25, 2002 Abgenix Announces Raymond Withy, Ph.D. As Chief Executive Officer
April 23, 2002 Abgenix Reports First Quarter 2002 Results
April 15, 2002 Abgenix And Diabetogen Sign Second Agreement To Develop Antibody Therapy Against Autoimmune Disease
March 22, 2002 Abgenix Announces Death of Board Member Joseph E. Maroun
February 27, 2002 Abgenix, Inc. Announces Pricing Of Private Offering Of Convertible Subordinated Notes
February 26, 2002 Abgenix, Inc. Announces Proposed Private Offering Of Convertible Subordinated Notes
February 19, 2002 Abgenix Announces Executive Promotions In Clinical Development
January 29, 2002 Abgenix Reports Year End 2001 Financial Results
January 15, 2002 Abgenix Announces 2001 Year-end Financial Results Conference Call
January 08, 2002 Abgenix Announces Initiation of a Phase 2 Clinical Trial of ABX-EGF in Combination With Chemotherapy in Patients With Colorectal Cancer
January 07, 2002 Abgenix Files IND Application For ABX-MA1 In Melanoma
January 03, 2002 Abgenix Initiates Phase 2 Clinical Trial Of ABX-EGF In Prostate Cancer
January 03, 2002 Abgenix Releases Results Of A Phase 2a Study With ABX-IL8 In Rheumatoid Arthritis
January 02, 2002 Abgenix Files IND Application for ABX-IL8 in Cancer

 
2001 Abgenix Press Releases
Date Title  (click to view the full text PDF)
December 27, 2001 Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer
December 04, 2001 Abgenix Introduces Enhanced Version of XenoMouse Technology
November 26, 2001 Abgenix Acquires Rights To Novel Cancer Target
November 19, 2001 Abgenix Announces CEO Succession Plan
November 13, 2001 Abgenix Acquires Catalytic Antibody Technology
November 02, 2001 Abgenix Licenses From Gliatech Antibody Product Candidates For Cardiovascular And Inflammatory Diseases
October 23, 2001 Abgenix Reports Third Quarter 2001 Financial Results
September 24, 2001 Abgenix Names H. David Miller Vice President, Information Technology
September 20, 2001 Abgenix Submits Ind Application To FDA For ABX-IL8 In Leading Pulmonary Disease
September 04, 2001 Abgenix Appoints Bruce A. Keyt Vice President, Preclinical Development
August 14, 2001 Abgenix And Agensys Enter Technology License Collaboration To Discover And Develop Human Therapeutic Antibodies Against Cancer
July 31, 2001 Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Non-Small Cell Lung Cancer
July 24, 2001 Abgenix And Curagen Scientists Discover And Select Additional 49 Novel Antibody Drug Targets For Development
July 24, 2001 Abgenix Reports Second Quarter 2001 Results
July 10, 2001 Abgenix Reaches Milestone In Antibody Collaboration With Amgen
June 29, 2001 MDS Proteomics And Abgenix Announce Exclusive Agreement To Develop Proteomic-Based Antibody Therapies
June 12, 2001 Abgenix Enters Xenomouse™ Technology Collaboration With Biogen To Generate Fully Human Antibodies
June 07, 2001 Abgenix Expands Antibody Agreement With Centocor
May 14, 2001 Tolerability Demonstrated by ABX-EGF as Monotherapy in Advanced Cancers
April 24, 2001 Abgenix Reports First Quarter 2001 Results
April 18, 2001 Abgenix And Immunex To Initiate Phase 2 Clinical Trial Of ABX-EGF In Kidney Cancer
March 29, 2001 Abgenix Expands Antibody Agreements With Chiron
March 27, 2001 Progenics Pharmaceuticals And Cytogen Create Fully Human Monoclonal Antibodies For Prostate Cancer Therapy Through Collaboration With Abgenix
March 27, 2001 Abgenix’s ABX-IL8 Antibody Shows Anti-Angiogenic And Anti-Tumor Activity In Cancer Cells
March 26, 2001 Abgenix And Diabetogen Form Collaboration To Develop Anti-Cd28 Antibody Therapy
March 05, 2001 Abgenix’s ABX-IL8 Antibody Associated With Statistically Significant Improvement In Psoriasis
February 23, 2001 Abgenix To Pay For Immgenics Acquisition With Cash Rather Than With Stock
February 21, 2001 Abgenix Appoints Susan Thorner Vice President, General Counsel And Secretary
February 05, 2001 Abgenix And Celltech Enter Technology Licensing And Co-Development Agreement
January 31, 2001 Lexicon Genetics Delivers Thirteen Novel Antigens To Abgenix For Antibody Development
January 30, 2001 Abgenix Reports Year End 2000 Financial Results
January 29, 2001 Abgenix Enters Exclusive Manufacturing Agreement With Lonza Biologics
January 22, 2001 Abgenix Announces 2000 Year-End Financial Results Conference Call
January 09, 2001 Abgenix Extends Antibody Collaboration With Amgen
January 09, 2001 Abgenix Extends Antibody Collaboration With Pfizer
January 08, 2001 Abgenix And Dyax To Collaborate On Novel Antibody Technology
January 05, 2001 Raymond M. Withy Promoted To President Of Abgenix
January 03, 2001 Abgenix To Proceed With Phase IIb Study Of ABX-IL8 In Psoriasis
January 03, 2001 Lexicon Genetics And Abgenix Enter Drug Target Validation Collaboration
January 02, 2001 Abgenix Receives Additional Patent Grant For Xenomouse™ Technology